nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—mouth—Crohn's disease	0.0607	0.264	CbGeAlD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IKZF1—Crohn's disease	0.0484	0.088	CbGpPWpGaD
Plerixafor—CXCR4—Binding and entry of HIV virion—CD4—Crohn's disease	0.0469	0.0853	CbGpPWpGaD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—ACKR2—Crohn's disease	0.039	0.0709	CbGpPWpGaD
Plerixafor—CXCR4—epithelium—Crohn's disease	0.0353	0.153	CbGeAlD
Plerixafor—CXCR4—smooth muscle tissue—Crohn's disease	0.034	0.148	CbGeAlD
Plerixafor—CXCR4—mammalian vulva—Crohn's disease	0.0306	0.133	CbGeAlD
Plerixafor—CXCR4—lymphoid tissue—Crohn's disease	0.0272	0.118	CbGeAlD
Plerixafor—CXCR4—digestive system—Crohn's disease	0.0269	0.117	CbGeAlD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CCR9—Crohn's disease	0.0256	0.0466	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—CCR9—Crohn's disease	0.0205	0.0373	CbGpPWpGaD
Plerixafor—CXCR4—Early Phase of HIV Life Cycle—CD4—Crohn's disease	0.0172	0.0313	CbGpPWpGaD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CCR6—Crohn's disease	0.017	0.0309	CbGpPWpGaD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IL3—Crohn's disease	0.0166	0.0303	CbGpPWpGaD
Plerixafor—CXCR4—lymph node—Crohn's disease	0.0153	0.0667	CbGeAlD
Plerixafor—Eye swelling—Mesalazine—Crohn's disease	0.0148	0.0672	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—ACKR2—Crohn's disease	0.0147	0.0267	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—MLN—Crohn's disease	0.0139	0.0253	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—CCR6—Crohn's disease	0.0136	0.0247	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—ACKR2—Crohn's disease	0.0115	0.0209	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—JAK2—Crohn's disease	0.0114	0.0208	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.00984	0.0179	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCR9—Crohn's disease	0.00964	0.0175	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.00932	0.017	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—SMAD3—Crohn's disease	0.00844	0.0154	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—CCR9—Crohn's disease	0.00813	0.0148	CbGpPWpGaD
Plerixafor—Platelet count decreased—Mesalazine—Crohn's disease	0.00812	0.0368	CcSEcCtD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.00754	0.0137	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—ACKR2—Crohn's disease	0.00749	0.0136	CbGpPWpGaD
Plerixafor—Upset stomach—Mesalazine—Crohn's disease	0.00737	0.0334	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—MLN—Crohn's disease	0.0071	0.0129	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.00701	0.0128	CbGpPWpGaD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IL1B—Crohn's disease	0.00686	0.0125	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00646	0.0118	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCR6—Crohn's disease	0.00638	0.0116	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00601	0.0109	CbGpPWpGaD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CXCL8—Crohn's disease	0.00547	0.00995	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—CCR6—Crohn's disease	0.00538	0.0098	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—RBX1—Crohn's disease	0.00521	0.00948	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.005	0.00909	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CCR9—Crohn's disease	0.00492	0.00896	CbGpPWpGaD
Plerixafor—Musculoskeletal pain—Mesalazine—Crohn's disease	0.00489	0.0222	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—GPR65—Crohn's disease	0.00458	0.00833	CbGpPWpGaD
Plerixafor—CXCR4—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.0044	0.00801	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—JAK2—Crohn's disease	0.00433	0.00788	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.00428	0.00779	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—CD4—Crohn's disease	0.0041	0.00747	CbGpPWpGaD
Plerixafor—Immune system disorder—Mercaptopurine—Crohn's disease	0.00404	0.0183	CcSEcCtD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IL6—Crohn's disease	0.00402	0.00731	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—MLN—Crohn's disease	0.00401	0.0073	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—ACKR2—Crohn's disease	0.00384	0.007	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.00377	0.00686	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MLN—Crohn's disease	0.00364	0.00663	CbGpPWpGaD
Plerixafor—Arthralgia—Mercaptopurine—Crohn's disease	0.00331	0.015	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00329	0.0149	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CCR6—Crohn's disease	0.00326	0.00593	CbGpPWpGaD
Plerixafor—Orthostatic hypotension—Mesalazine—Crohn's disease	0.0032	0.0145	CcSEcCtD
Plerixafor—Abdominal discomfort—Azathioprine—Crohn's disease	0.00319	0.0145	CcSEcCtD
Plerixafor—CXCR4—CXCR4-mediated signaling events—STAT3—Crohn's disease	0.00318	0.00578	CbGpPWpGaD
Plerixafor—Skin disorder—Mercaptopurine—Crohn's disease	0.00308	0.014	CcSEcCtD
Plerixafor—Abdominal distension—Mesalazine—Crohn's disease	0.00305	0.0138	CcSEcCtD
Plerixafor—Abdominal discomfort—Mesalazine—Crohn's disease	0.00291	0.0132	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00289	0.0131	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—PTGER4—Crohn's disease	0.00287	0.00522	CbGpPWpGaD
Plerixafor—CXCR4—HIV Life Cycle—CD4—Crohn's disease	0.00279	0.00508	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CCR9—Crohn's disease	0.00278	0.00506	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00274	0.0124	CcSEcCtD
Plerixafor—Haemoglobin—Azathioprine—Crohn's disease	0.00268	0.0121	CcSEcCtD
Plerixafor—Haemorrhage—Azathioprine—Crohn's disease	0.00266	0.0121	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—GPR65—Crohn's disease	0.00259	0.00471	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CCR9—Crohn's disease	0.00253	0.0046	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RSPO3—Crohn's disease	0.00246	0.00447	CbGpPWpGaD
Plerixafor—Haemoglobin—Mesalazine—Crohn's disease	0.00244	0.0111	CcSEcCtD
Plerixafor—Haemorrhage—Mesalazine—Crohn's disease	0.00243	0.011	CcSEcCtD
Plerixafor—Immune system disorder—Azathioprine—Crohn's disease	0.00241	0.0109	CcSEcCtD
Plerixafor—Connective tissue disorder—Mesalazine—Crohn's disease	0.00238	0.0108	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—GPR65—Crohn's disease	0.00235	0.00427	CbGpPWpGaD
Plerixafor—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00234	0.0106	CcSEcCtD
Plerixafor—CXCR4—Disease—SEL1L—Crohn's disease	0.00233	0.00424	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ACKR2—Crohn's disease	0.00227	0.00413	CbGpPWpGaD
Plerixafor—Immune system disorder—Mesalazine—Crohn's disease	0.00219	0.00994	CcSEcCtD
Plerixafor—Diarrhoea—Mercaptopurine—Crohn's disease	0.00217	0.00986	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—MLN—Crohn's disease	0.00215	0.00392	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Azathioprine—Crohn's disease	0.00215	0.00976	CcSEcCtD
Plerixafor—Mental disorder—Mesalazine—Crohn's disease	0.00213	0.00964	CcSEcCtD
Plerixafor—Erythema—Mesalazine—Crohn's disease	0.00211	0.00958	CcSEcCtD
Plerixafor—Malaise—Azathioprine—Crohn's disease	0.00209	0.00948	CcSEcCtD
Plerixafor—CXCR4—Disease—LTF—Crohn's disease	0.00209	0.0038	CbGpPWpGaD
Plerixafor—Flatulence—Mesalazine—Crohn's disease	0.00208	0.00944	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CXCL8—Crohn's disease	0.00206	0.00374	CbGpPWpGaD
Plerixafor—Vomiting—Mercaptopurine—Crohn's disease	0.00202	0.00916	CcSEcCtD
Plerixafor—Rash—Mercaptopurine—Crohn's disease	0.002	0.00908	CcSEcCtD
Plerixafor—Dermatitis—Mercaptopurine—Crohn's disease	0.002	0.00908	CcSEcCtD
Plerixafor—Arthralgia—Azathioprine—Crohn's disease	0.00197	0.00895	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TAGAP—Crohn's disease	0.00197	0.00358	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.00196	0.00889	CcSEcCtD
Plerixafor—Ill-defined disorder—Mesalazine—Crohn's disease	0.00196	0.00889	CcSEcCtD
Plerixafor—Discomfort—Azathioprine—Crohn's disease	0.00195	0.00885	CcSEcCtD
Plerixafor—CXCR4—HIV Infection—CD4—Crohn's disease	0.00193	0.00351	CbGpPWpGaD
Plerixafor—Malaise—Mesalazine—Crohn's disease	0.0019	0.00864	CcSEcCtD
Plerixafor—Syncope—Mesalazine—Crohn's disease	0.00189	0.00859	CcSEcCtD
Plerixafor—Nausea—Mercaptopurine—Crohn's disease	0.00189	0.00856	CcSEcCtD
Plerixafor—Loss of consciousness—Mesalazine—Crohn's disease	0.00186	0.00842	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CCR6—Crohn's disease	0.00184	0.00335	CbGpPWpGaD
Plerixafor—Skin disorder—Azathioprine—Crohn's disease	0.00184	0.00834	CcSEcCtD
Plerixafor—Arthralgia—Mesalazine—Crohn's disease	0.0018	0.00816	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.00179	0.0081	CcSEcCtD
Plerixafor—Discomfort—Mesalazine—Crohn's disease	0.00178	0.00806	CcSEcCtD
Plerixafor—Dry mouth—Mesalazine—Crohn's disease	0.00176	0.00798	CcSEcCtD
Plerixafor—CXCR4—G alpha (i) signalling events—CXCL8—Crohn's disease	0.00174	0.00316	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.00172	0.00782	CcSEcCtD
Plerixafor—Anaphylactic shock—Mesalazine—Crohn's disease	0.00172	0.00782	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RSPO3—Crohn's disease	0.00172	0.00313	CbGpPWpGaD
Plerixafor—Shock—Mesalazine—Crohn's disease	0.0017	0.00769	CcSEcCtD
Plerixafor—Nervous system disorder—Mesalazine—Crohn's disease	0.00169	0.00767	CcSEcCtD
Plerixafor—CXCR4—Disease—GCKR—Crohn's disease	0.00168	0.00307	CbGpPWpGaD
Plerixafor—Skin disorder—Mesalazine—Crohn's disease	0.00167	0.00759	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CCR6—Crohn's disease	0.00167	0.00305	CbGpPWpGaD
Plerixafor—Hyperhidrosis—Mesalazine—Crohn's disease	0.00167	0.00756	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00163	0.00741	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SEL1L—Crohn's disease	0.00163	0.00297	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PTGER4—Crohn's disease	0.00162	0.00295	CbGpPWpGaD
Plerixafor—Abdominal distension—Prednisone—Crohn's disease	0.00161	0.00732	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00157	0.00712	CcSEcCtD
Plerixafor—Feeling abnormal—Azathioprine—Crohn's disease	0.00156	0.00707	CcSEcCtD
Plerixafor—Insomnia—Mesalazine—Crohn's disease	0.00156	0.00707	CcSEcCtD
Plerixafor—Paraesthesia—Mesalazine—Crohn's disease	0.00155	0.00702	CcSEcCtD
Plerixafor—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00155	0.00702	CcSEcCtD
Plerixafor—Dyspnoea—Mesalazine—Crohn's disease	0.00154	0.00697	CcSEcCtD
Plerixafor—Dyspepsia—Mesalazine—Crohn's disease	0.00152	0.00688	CcSEcCtD
Plerixafor—Abdominal pain—Azathioprine—Crohn's disease	0.0015	0.00679	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CCR9—Crohn's disease	0.00149	0.00272	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SLC11A1—Crohn's disease	0.00149	0.00271	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.00149	0.00675	CcSEcCtD
Plerixafor—Fatigue—Mesalazine—Crohn's disease	0.00149	0.00674	CcSEcCtD
Plerixafor—Constipation—Mesalazine—Crohn's disease	0.00147	0.00669	CcSEcCtD
Plerixafor—Pain—Mesalazine—Crohn's disease	0.00147	0.00669	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PTGER4—Crohn's disease	0.00147	0.00268	CbGpPWpGaD
Plerixafor—Feeling abnormal—Mesalazine—Crohn's disease	0.00142	0.00644	CcSEcCtD
Plerixafor—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00141	0.00639	CcSEcCtD
Plerixafor—Hypersensitivity—Azathioprine—Crohn's disease	0.00139	0.00632	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GPR65—Crohn's disease	0.00139	0.00252	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—IL3—Crohn's disease	0.00138	0.00251	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.00138	0.00251	CbGpPWpGaD
Plerixafor—Urticaria—Mesalazine—Crohn's disease	0.00137	0.00621	CcSEcCtD
Plerixafor—Abdominal pain—Mesalazine—Crohn's disease	0.00136	0.00618	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—RASGRP1—Crohn's disease	0.00134	0.00243	CbGpPWpGaD
Plerixafor—Diarrhoea—Azathioprine—Crohn's disease	0.00129	0.00587	CcSEcCtD
Plerixafor—Haemoglobin—Prednisone—Crohn's disease	0.00129	0.00585	CcSEcCtD
Plerixafor—Haemorrhage—Prednisone—Crohn's disease	0.00128	0.00582	CcSEcCtD
Plerixafor—CXCR4—Disease—RBX1—Crohn's disease	0.00128	0.00232	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HSPA1B—Crohn's disease	0.00128	0.00232	CbGpPWpGaD
Plerixafor—Hypersensitivity—Mesalazine—Crohn's disease	0.00127	0.00576	CcSEcCtD
Plerixafor—Connective tissue disorder—Prednisone—Crohn's disease	0.00126	0.00572	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—IL3—Crohn's disease	0.00125	0.00228	CbGpPWpGaD
Plerixafor—Dizziness—Azathioprine—Crohn's disease	0.00125	0.00568	CcSEcCtD
Plerixafor—Asthenia—Mesalazine—Crohn's disease	0.00124	0.00561	CcSEcCtD
Plerixafor—Pruritus—Mesalazine—Crohn's disease	0.00122	0.00553	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—RASGRP1—Crohn's disease	0.00121	0.00221	CbGpPWpGaD
Plerixafor—Vomiting—Azathioprine—Crohn's disease	0.0012	0.00546	CcSEcCtD
Plerixafor—Rash—Azathioprine—Crohn's disease	0.00119	0.00541	CcSEcCtD
Plerixafor—Dermatitis—Azathioprine—Crohn's disease	0.00119	0.00541	CcSEcCtD
Plerixafor—Headache—Azathioprine—Crohn's disease	0.00119	0.00538	CcSEcCtD
Plerixafor—Diarrhoea—Mesalazine—Crohn's disease	0.00118	0.00535	CcSEcCtD
Plerixafor—Immune system disorder—Prednisone—Crohn's disease	0.00116	0.00526	CcSEcCtD
Plerixafor—Dizziness—Mesalazine—Crohn's disease	0.00114	0.00517	CcSEcCtD
Plerixafor—Mental disorder—Prednisone—Crohn's disease	0.00112	0.0051	CcSEcCtD
Plerixafor—Nausea—Azathioprine—Crohn's disease	0.00112	0.0051	CcSEcCtD
Plerixafor—CXCR4—Disease—UBE2D1—Crohn's disease	0.00112	0.00204	CbGpPWpGaD
Plerixafor—Erythema—Prednisone—Crohn's disease	0.00112	0.00507	CcSEcCtD
Plerixafor—Vomiting—Mesalazine—Crohn's disease	0.0011	0.00497	CcSEcCtD
Plerixafor—Rash—Mesalazine—Crohn's disease	0.00109	0.00493	CcSEcCtD
Plerixafor—Dermatitis—Mesalazine—Crohn's disease	0.00109	0.00493	CcSEcCtD
Plerixafor—Headache—Mesalazine—Crohn's disease	0.00108	0.0049	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CXCL8—Crohn's disease	0.00105	0.00191	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Prednisone—Crohn's disease	0.00104	0.0047	CcSEcCtD
Plerixafor—Nausea—Mesalazine—Crohn's disease	0.00102	0.00464	CcSEcCtD
Plerixafor—Malaise—Prednisone—Crohn's disease	0.00101	0.00457	CcSEcCtD
Plerixafor—Syncope—Prednisone—Crohn's disease	0.001	0.00455	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CCR6—Crohn's disease	0.000988	0.0018	CbGpPWpGaD
Plerixafor—Loss of consciousness—Prednisone—Crohn's disease	0.000982	0.00446	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—IL2RA—Crohn's disease	0.000968	0.00176	CbGpPWpGaD
Plerixafor—Arthralgia—Prednisone—Crohn's disease	0.000951	0.00432	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000945	0.00429	CcSEcCtD
Plerixafor—Discomfort—Prednisone—Crohn's disease	0.00094	0.00426	CcSEcCtD
Plerixafor—Anaphylactic shock—Prednisone—Crohn's disease	0.000912	0.00414	CcSEcCtD
Plerixafor—Shock—Prednisone—Crohn's disease	0.000897	0.00407	CcSEcCtD
Plerixafor—Nervous system disorder—Prednisone—Crohn's disease	0.000894	0.00406	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RBX1—Crohn's disease	0.000894	0.00163	CbGpPWpGaD
Plerixafor—Skin disorder—Prednisone—Crohn's disease	0.000886	0.00402	CcSEcCtD
Plerixafor—Hyperhidrosis—Prednisone—Crohn's disease	0.000882	0.004	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—IL2RA—Crohn's disease	0.000879	0.0016	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTGER4—Crohn's disease	0.00087	0.00158	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000831	0.00377	CcSEcCtD
Plerixafor—Insomnia—Prednisone—Crohn's disease	0.000825	0.00374	CcSEcCtD
Plerixafor—Paraesthesia—Prednisone—Crohn's disease	0.000819	0.00371	CcSEcCtD
Plerixafor—Dyspepsia—Prednisone—Crohn's disease	0.000803	0.00364	CcSEcCtD
Plerixafor—CXCR4—Disease—SMAD3—Crohn's disease	0.000801	0.00146	CbGpPWpGaD
Plerixafor—Fatigue—Prednisone—Crohn's disease	0.000786	0.00357	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—UBE2D1—Crohn's disease	0.000784	0.00143	CbGpPWpGaD
Plerixafor—Constipation—Prednisone—Crohn's disease	0.00078	0.00354	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RIPK2—Crohn's disease	0.00076	0.00138	CbGpPWpGaD
Plerixafor—Feeling abnormal—Prednisone—Crohn's disease	0.000752	0.00341	CcSEcCtD
Plerixafor—Gastrointestinal pain—Prednisone—Crohn's disease	0.000746	0.00338	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—IL3—Crohn's disease	0.000741	0.00135	CbGpPWpGaD
Plerixafor—Urticaria—Prednisone—Crohn's disease	0.000724	0.00329	CcSEcCtD
Plerixafor—Abdominal pain—Prednisone—Crohn's disease	0.000721	0.00327	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RASGRP1—Crohn's disease	0.000717	0.0013	CbGpPWpGaD
Plerixafor—Hypersensitivity—Prednisone—Crohn's disease	0.000672	0.00305	CcSEcCtD
Plerixafor—Asthenia—Prednisone—Crohn's disease	0.000654	0.00297	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—JAK2—Crohn's disease	0.000651	0.00118	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SOCS1—Crohn's disease	0.000649	0.00118	CbGpPWpGaD
Plerixafor—Pruritus—Prednisone—Crohn's disease	0.000645	0.00293	CcSEcCtD
Plerixafor—Diarrhoea—Prednisone—Crohn's disease	0.000624	0.00283	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—TYK2—Crohn's disease	0.000619	0.00113	CbGpPWpGaD
Plerixafor—Dizziness—Prednisone—Crohn's disease	0.000603	0.00274	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL8—Crohn's disease	0.000594	0.00108	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—JAK2—Crohn's disease	0.000591	0.00108	CbGpPWpGaD
Plerixafor—Vomiting—Prednisone—Crohn's disease	0.00058	0.00263	CcSEcCtD
Plerixafor—Rash—Prednisone—Crohn's disease	0.000575	0.00261	CcSEcCtD
Plerixafor—Dermatitis—Prednisone—Crohn's disease	0.000574	0.00261	CcSEcCtD
Plerixafor—Headache—Prednisone—Crohn's disease	0.000571	0.00259	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SMAD3—Crohn's disease	0.000561	0.00102	CbGpPWpGaD
Plerixafor—Nausea—Prednisone—Crohn's disease	0.000542	0.00246	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CXCL8—Crohn's disease	0.000539	0.000981	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TYK2—Crohn's disease	0.000522	0.000951	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL2RA—Crohn's disease	0.000519	0.000945	CbGpPWpGaD
Plerixafor—CXCR4—Disease—JAK2—Crohn's disease	0.000498	0.000907	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CD4—Crohn's disease	0.000472	0.00086	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTGS2—Crohn's disease	0.000469	0.000854	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TYK2—Crohn's disease	0.000366	0.000666	CbGpPWpGaD
Plerixafor—CXCR4—Disease—STAT3—Crohn's disease	0.000366	0.000666	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—JAK2—Crohn's disease	0.000349	0.000635	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL8—Crohn's disease	0.000319	0.00058	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6—Crohn's disease	0.000303	0.000551	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STAT3—Crohn's disease	0.000256	0.000466	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL6—Crohn's disease	0.000255	0.000465	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6—Crohn's disease	0.000179	0.000326	CbGpPWpGaD
